First Republic Investment Management Inc. lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,408 shares of the medical research company's stock after buying an additional 188 shares during the period. First Republic Investment Management Inc.'s holdings in Bio-Rad Laboratories were worth $1,004,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. SeaCrest Wealth Management LLC acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth about $26,000. Private Trust Co. NA boosted its stake in shares of Bio-Rad Laboratories by 230.0% during the third quarter. Private Trust Co. NA now owns 66 shares of the medical research company's stock worth $28,000 after buying an additional 46 shares during the period. Atlas Capital Advisors LLC acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth about $50,000. Allworth Financial LP boosted its stake in shares of Bio-Rad Laboratories by 414.8% during the third quarter. Allworth Financial LP now owns 139 shares of the medical research company's stock worth $58,000 after buying an additional 112 shares during the period. Finally, Sentry Investment Management LLC boosted its stake in shares of Bio-Rad Laboratories by 16.5% during the second quarter. Sentry Investment Management LLC now owns 148 shares of the medical research company's stock worth $73,000 after buying an additional 21 shares during the period. Institutional investors and hedge funds own 64.35% of the company's stock.
Get
Bio-Rad Laboratories alerts:
Bio-Rad Laboratories Price Performance
BIO stock opened at $470.88 on Friday. The firm has a 50 day moving average of $432.84 and a 200-day moving average of $447.37. Bio-Rad Laboratories, Inc. has a 12-month low of $344.63 and a 12-month high of $670.61. The company has a current ratio of 5.50, a quick ratio of 4.30 and a debt-to-equity ratio of 0.14. The company has a market cap of $14.04 billion, a price-to-earnings ratio of -2.33 and a beta of 0.92.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. TheStreet downgraded shares of Bio-Rad Laboratories from a "c" rating to a "d+" rating in a research report on Thursday, October 27th. Credit Suisse Group reduced their price objective on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating for the company in a research report on Friday, October 28th. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, January 18th. Finally, Royal Bank of Canada assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, December 6th. They issued an "outperform" rating and a $565.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $651.25.
Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Read More
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
